trial

Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia

NCTId NCT01267188
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 10 (estimated)
Sponsored by Neurocrine Biosciences
Primary completion 2011-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
10 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2011-01
Primary completion
2011-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
NBI-98854

Sponsors

Neurocrine BiosciencesLead Sponsor

Sites

0 total

Linked catalysts

1
Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia — primary completion2011-03

Facts & assertions

4 sourced
Enrollment
10
Phase
PHASE2
Primary Completion Date
2011-03
Status
COMPLETED
relationships
The graph out of here
drug
NBI-98854
drug
lead_sponsor
Neurocrine Biosciences
company
indication
Tardive Dyskinesia
indication
Tardive Dyskinesia
indication